Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2730 Pharmacodynamic Study in Photosensitive Epilepsy
NCT03603639Phase 2Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of E2730 in photosensitive epilepsy (PSE) (6 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Mean Change From Baseline in the Standard Photosensitivity Response (SPR) in the Most Sensitive Eye Condition. Started Jul 2018; status: terminated.
02
Drugs
E2730
03
Conditions
photosensitive epilepsy (PSE)
Beyond the preview
Go deeper on NCT03603639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603639.